Business
Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement
Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ȁ...
About this update from Devonian Health Group, Inc.
[{"type":"text","content":"Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n Devonian Health Group Inc. (“\n \n Devonian\n \n ” or the “\n \n Corporation\n \n ”) (\n \n TSXV: GSD; OTCQB: DVHGF\n \n ), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, provides today corporate update:\n \n\n\n Thykamine™: Pipeline Advances on Multiple Fronts\n \n\n\n On the manufacturing front, batch-to-batch consistency of Thykamine™ has been validated through advanced analytical techniques, including High Performance Liquid Chromatography–Mass Spectrometry (HPLC-MS) and Nuclear Magnetic Resonance (NMR). These results highlight the robust quality and reliability of our production process for this first-in-class therapeutic.\n \n\n Pre-clinical programs are progressing to further demonstrate Thykamine™’s unique dual action on both inflammation and fibrosis pathways. Current studies in Metabolic Associated Steatohepatitis (MASH) and pulmonary fibrosis models are designed to confirm its potential as a broadly applicable anti-inflammatory and anti-fibrotic drug. Data readouts are expected in fall 2025 and are anticipated to support expansion into multiple high-value indications.\n \n\n In parallel, the company is advancing development of oral formulations (liquid and capsule) to unlock additional opportunities in Ulcerative Colitis and other diseases where oral delivery is preferred. This strategic diversification broadens Thykamine™’s market reach and strengthens its long-term commercial potential.\n \n\n Finally, a U.S. survey of dermatologists confirmed the acceptance of Thykamine™ cream in pediatric patients with mild-to-moderate atopic dermatitis, further supporting its clinical relevance and commercial potential. This positive outcome validates Devonian’s strategy to target this underserved population and further reinforces the commercial viability of Thykamine™ across multiple therapeutic areas.\n \n\n\n Altius Healthcare LP\n \n\n\n As announced on February 7, 2025, the distribution license for Dexlansoprazole was not renewed and officially expired on April 17, 2025. The Corporation has s...